The Asia Pacific Conference of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) was held at Keio Plaza Hotel in Shinjuku, Tokyo, for 4 days from September 9 to 11, 2018. The conference has been held biennially in the Asia-Pacific region, and this was the 8th event. With formal introduction of Cost-effectiveness Evaluation from the next fiscal year, there were a large number of participants from Japan and other countries.
During the event, many presentations were made each day. We also made presentations, as summarized below:
September 9（Sun）BREAKOUT SESSION (Issue Panel Presentation)
“How Will Patient Centricity Be Captured in the Japanese HTA and Healthcare Reform?”
Moderator: Adrian Towse, MA, MPhil.
Panelists: Shunya Ikeda, Md, Makoto Kobayashi, PhD, MEng, Durhane Wong-Rieger, Phd, MA.
September 10（Mon）BREAKOUT SESSION (Workshop Presentation)
“Japanese HTA and Pricing: Current Methods and Future Potential”
Isao Kamae, MD, DrPH, Makoto Kobayashi, PhD, MEng, PhD, MEng, Parashar Patel, MPA, Peter J. Neumann, ScD.
September 9（Sun）Poster Presentation
COST-MINIMIZATION ANALYSIS OF VERCISE DBS SYSTEM FOR PARKINSON’S DISEASE IN JAPAN.
Kitamura A, Sato T, Priest V, Inoue S, Kobayashi M.
ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN JAPAN.Kamae I, Kitamura A, Sakurai M, Yamamoto M, Inoue S, Shibahara H, Kobayashi M.
September 10（Mon）Poster Presentation
AN ECONOMIC EVALUATION OF MIGALASTAT VERSUS ERT FOR THE TREATMENT OF FABRY DISEASE IN JAPAN.Inoue S, Kobayashi M, Pang F.
September 11（Tue）Poster Presentation
PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE FOR HEART DISEASE PATIENTS IN JAPAN.
Noto S, Fukuda T, Saito S, Shimozuma K, Ikeda S, Shiroiwa T, Igarashi A, Ishida H, Moriwaki K, Kobayashi M.
CURRENT STATUS OF REAL WORLD DATA USING FOR CONDUCTING COST-EFFECTIVENESS ASSESSMENTS IN JAPAN.Hanada K, Akazawa M
Our exhibition booth
For a fresh start at the event held in our country this year, all staff members worked to newly design our exhibition booth.
With folded paper cranes and Japanese-style promotion goods, we could successfully receive and communicate with many visitors.
We were frequently asked about Health Technology Assessment (HTA) in Japan, realizing that there is an increasing interest in this issue toward the formal introduction of Cost-effectiveness Evaluation, which has been tentatively adopted since 2016. The large number of participants expecting for its future development was also impressive.
Be able to communicate with many participants who visited our booth made our exhibition very productive. The event in Japan ended with great success.
Our booth at the Conference